Check for updates

OPEN ACCESS

EDITED BY Yu Sun, Princeton University, United States

REVIEWED BY Yixiao Wang, Southeast University, China Constantino Martinez, University of Murcia, Spain

*CORRESPONDENCE Li Zheng zhenglis1270755@163.com Yan Wang wanyan4127@bjhmoh.cn

SPECIALTY SECTION

This article was submitted to Cardiovascular Pharmacology and Drug Discovery, a section of the journal Frontiers in Cardiovascular Medicine

RECEIVED 18 October 2022 ACCEPTED 23 November 2022 PUBLISHED 09 December 2022

CITATION

Zheng L, Xia B, Yuan Y, Wang Y and Wang Y (2022) Low-molecular-weight heparin in addition to low-dose aspirin for preventing preeclampsia and its complications: A systematic review and meta-analysis. *Front. Cardiovasc. Med.* 9:1073148. doi: 10.3389/fcvm.2022.1073148

COPYRIGHT

© 2022 Zheng, Xia, Yuan, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License

(CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Low-molecular-weight heparin in addition to low-dose aspirin for preventing preeclampsia and its complications: A systematic review and meta-analysis

Li Zheng^{1*}, Binbin Xia², Yuan Yuan³, Yuran Wang⁴ and Yan Wang^{5*}

¹Department of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, China, ²Department of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China, ³Department of Dermatology, Gansu Provincial Central Hospital, Lanzhou, China, ⁴Obstetrics and Gynecology Department, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, China, ⁵Department of Cardiovascular Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

Background: In this systematic review, we aimed to investigate the efficacy and safety of adding low-molecular-weight heparin (LMWH) or unfractionated heparin to low-dose aspirin (LDA) started \leq 16 weeks'gestation in the prevention of preeclampsia (PE) in high-risk women.

Methods: PubMed, Cochrane Library, Embase, and ClinicalTrials.gov databases were searched from their inception to April 2022 for randomized controlled trials (RCTs) that to determine whether the combined treatment of LMWH and LDA is better than single anticoagulant drugs in preventing PE and improving live birth rate of fetus in high-risk women with pregnancy \leq 16 weeks. We also searched Embase, OVID MEDLINE and OVID MEDLINE in-process using the OVID platform.

Results: 14 RCTs involving 1,966 women were found. The LMWH (or unfractionated heparin) and LDA groups included 1,165 wemen, and the LDA group included 960 women. The meta-analysis showed that the addition of LMWH to LDA reduced the risk of PE (RR: 0.59, 95% CI: 0.44-0.79, P < 0.05), small-for-gestational age (SGA, RR: 0.71, 95% CI: 0.52-0.97, P = 0.03), fetal and neonatal death (RR: 0.45, 95% CI: 0.23-0.88, P = 0.02) and gestational hypertension (RR: 0.47, 95% CI: 0.25-0.90, P = 0.02). It is worth emphasizing that LMWH (or unfractionated heparin) combined with LDA did not increase the risk of bleeding.

Conclusions: LMWH combined with LDA can effectively improve the pregnancy outcome of women with high risk factors for PE and its complications. Although this study showed that combined medication also did not increase the risk of bleeding, but such results lack the support of large sample size studies. The clinical safety analysis of LMWH combined with LDA in patients with PE should be more carried out.

KEYWORDS

low-dose-aspirin, low-molecular-weight heparin, prevention, preeclampsia, meta-analysis

Introduction

Preeclampsia (PE) is characterized by hypertension and proteinuria, and it is one of the important factors leading to maternal and perinatal death. The incidence rate of all pregnant women is about 2-8% (1, 2). The main manifestations of PE are maternal and multiple organ and system damage, as well as adverse pregnancy outcomes such as fetal growth restriction (FGR) and placental abruption. At the same time, PE can have adverse effects on repregnancy. Women with a history of PE are 25-65% likely to have PE again, 3% may have placental abruption, and 10% may have FGR again (3). The causes are multifactorial, including dysinvasion of uterine spiral artery trophoblast, injury of vascular endothelial cells and transitional activation of maternal immune system (4-7). The dysfunction or disorder of hemostasis, coagulation, anticoagulation and fibrinolysis system caused by many factors can eventually lead to the abnormal increase of coagulation function and the decrease of fibrinolysis function, so that the blood is in a hypercoagulable state.

At present, there are evidence-based evidences that the application of aspirin in high-risk groups of PE can effectively prevent the onset of PE and reduce adverse pregnancy outcomes (8, 9). Studies have also confirmed that low molecular weight heparin (LMWH) reduces the incidence of PE, perinatal death and FGR in high-risk pregnant women, and improves the pregnancy outcome of patients (10, 11). In addition, because LMWH cannot pass through the placenta, there is almost no direct risk to the fetus, and massive hemorrhage or placental abruption are rarely observed in pregnant women treated with LMWH (12).

In recent years, some studies have reported the effect and safety of aspirin combined with LMWH in the prevention of PE and its complications. In this study, meta-analysis method was used to conduct a comprehensive evaluation of these related studies to make up for the small sample size of a single study. The primary purpose is to determine whether the combined treatment of LMWH and aspirin is better than single anticoagulant drugs in preventing PE and its complications in high-risk women with pregnancy ≤ 16 weeks.

Methods

We performed a meta-analysis and wrote the article by conforming to the requirements illustrated in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (13). We compared the treatment with LMWH or heparin (with low-dose aspirin) with LMWH alone or low-dose aspirin (LDA) alone in women at high risk of PE.

Search strategy

PubMed, Cochrane Library, Embase, and ClinicalTrials.gov databases were searched from their inception to April 2022. We also searched Embase, OVID MEDLINE and OVID MEDLINE in-process using the OVID platform. The search terms that we used in the Pubmed database were as follows: #1 "preeclampsia" [title/abstract] OR "preeclampsia" [title/abstract] OR "PE" [title/abstract] OR "celampsia" [title/abstract]; #2 "heparin" [title/abstract] OR "Low-Molecular-Weightheparin" [title/abstract] OR "LMWH" [title/abstract]; #3 "aspirin" [title/abstract]; #4 #1 AND #2 AND #3. The databases were searched for published studies in English, including systematic reviews and meta-analysis, that were related to the treatment with LMWH or heparin (with LDA) in women at high risk of PE. After the search is complete, the documents were exported in full text format.

Inclusion and exclusion criteria

Inclusion criteria were: (1) randomized controlled trials (RCTs) studies comparing LDA with LMWH or heparin for prevention of PE; (2) studies including women who had any known high risk factors for PE and its complications, such as adverse obstetric history of previous PE, small-for-gestational age (SGA) or FGR, placental abruption, and medical history including thrombophilia, autoimmune disease, and other chronic diseases; (3) published paper.

Animal experiments and non-RCTs were excluded from the meta-analysis. In addition, studies were excluded if they included other treatment options.

The primary outcomes were PE and live birth rate, with secondary outcomes including placental abruption, severe PE (sPE), gestational hypertension, FGR or SGA, fetal and neonatal death and HELLP (hemolysis, elevated liver enzymesand low platelet count) syndrome. We also analyzed the presence of adverse events such as intrapartum or postpartum hemorrhage.

In this context, it is recommended that women are diagnosed with PE if they present with the following severe features: systolic blood pressure of 140 mmHg or more or diastolic blood pressure of 90 mmHg or more on two occasions at least 4 h apart after 20weeks of gestation in a woman with a previously normal blood pressure plus proteinuria, defined asurinary excretion of 300 mg or more per 24 h urine collection (or this amount extrapolated from a timed collection)orc Protein/creatinine ratio of 0.3 mg/dL or more orc Dipstick reading of 2+(used only if other quantitativemethods not available) (14). The women are diagnosed with sPE when the following conditions are met: systolic blood pressure \geq 160 mm Hg and/or diastolic blood pressure \geq 110 mm Hg; Urine protein ic blood pressure more or the meria was strongly positive; brain nerve symptoms persist and worsen; persistent epigastric pain; serum aspartate aminotransferase significantly increased, creatinine $>106 \,\mu$ mol/L; hypoalbuminemia, pleural or peritoneal effusion, heart failure, pulmonary edema, oligohydramnios, abnormal blood system indicators and other manifestations may occur at the same time. In addition, the main distinction between SGA and FGR is that a SGA fetus may be small but not at increased risk of adverse perinatal outcome, while a fetus with size above the 10th percentile may be FGR and at increased risk of adverse perinatal and long-term outcome (15).

Data extraction

Two authors (BX and YY) independently screened and retrieved the relevant literatures. Then, after reading the title and abstract of the article, they excluded the studies that did not meet the inclusion criteria. Full texts of final selected articles and data extraction were performed independently by other 2 researchers (LZ and YW), and any discrepancies were resolved by discussion.

The extracted data included names of the first authors of selected articles, basic information on studies (research design, patient groups, interventions, doses of medications, number of patients, duration of treatment), characteristics of patients (gestational age, participant condition), and reported outcomes (PE, live birth rate, sPE, gestational hypertension, placental abruption, FGR or SGA, fetal and neonatal death, HELLP syndrome and intrapartum or postpartum hemorrhage).

Study quality

The risk of bias of RCTs was assessed using the Cochrane Collaboration's tool (16) based on seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Two reviewers (YY and BX) independently finished the quality assessments. In the case of a disagreement, a third reviewer (LZ) was involved in finally reaching a consensus through negotiation.

Statistical analysis

RevMan 5.3 software provided by the Cochrane Collaboration Network was used for meta-analysis of the included studies. The software was also used to draw a forest map. For continuous variables, data have been presented as the mean difference (MD) with 95% confidence interval (CI) between the experimental and control groups. For dichotomous outcome data, the risk ratio (RR) or odds ratio (OR) with 95% CI was calculated. The chi-square test was used to assess

heterogeneity between studies, and combined with I^2 to quantitatively judge the extent of heterogeneity. The fixedeffects model was applied at P > 0.1 and $I^2 < 40\%$, which showed that there was little heterogeneity between studies. Otherwise, the random-effects model was used for analysis (17).

Publication bias

Begg's and Egger's tests of asymmetry were performed using the statistical software Stata 12.0 to assess potential publication bias. The tests were also used to identify outliers (18).

Results

Study characteristics


Thousand six hundred and seventy eight articles were obtained from the search through the above mentioned databases. Of these, 1,146 articles were removed due to record duplication and 447 studies were excluded based on their titles and abstracts. Finally, a total of 14 studies that included 1,966 women were considered in the systematic review and metaanalysis based on the inclusion and exclusion criteria (Figure 1).

The baseline characteristics of the included studies were presented in the Table 1. Eight articles used enoxaparin (19, 20, 22, 24, 25, 27, 29, 30), three articles used dalteparin (21, 23, 26), one article used nadroparin (28), one did not specify the type of LMWH (32) and one used unfractionated heparin (31). The gestational age of included pregnant women varied among different studies, but all women were randomly divided between the first positive pregnancy test and 16 weeks' gestation. Because patients' conditions are heterogeneous across the different studies with different baseline characteristics, which may lead to heterogeneity in outcome measures, we performed subgroup analysis.

Risk of bias within studies

The Cochrane Collaboration's Risk of Bias tool (16) was used to evaluate the risk of bias of included studies. The results showed that the quality of most studies is acceptable. Most RCTs had an unclear risk of bias for allocation concealment, blinding of the outcome, and incomplete outcome data, considering that detailed information was not provided.

The highest risk of bias occurred in the blinding of participants and personnel. This is because neither study personnel nor participants in five studies (20–22, 26, 29) were blinded to treatment assignment, as placebo injections were not considered to be ethically acceptable during pregnancy in. Quality assessment of the included studies is shown in Figure 2.



Meta-analysis

Among all the included studies, six studies (20–22, 25, 26, 30) recruited women with a history of PE, two of which included only women with thrombophilia; eight studies (19, 23, 24, 27–29, 31, 32) recruited women with a history of miscarriages, one of them in women with thrombophilia and one of them including women with factor V Leiden mutation (FVL, a risk factor for deep vein thrombosis and pulmonary embolism). Due to the wide heterogeneity between the inclusion criteria of different studies, we performed subgroup analysis of the results according to the entry criteria.

Primary outcomes

PE

We observed that the data from ten studies (19–22, 25– 30) included (n = 1,452), the pooled results obtained using a fixed-effects model showed that the addition of LMWH to LDA reduced the risk of PE (RR: 0.59, 95% CI: 0.44–0.79, P < 0.05). In the subgroup analysis, the addition of LMWH to LDA reduced the risk of PE in women with a history of PE (RR: 0.62, 95% CI: 0.45–0.87, P < 0.05) and miscarriages (RR: 0.50, 95% CI: 0.27–0.90, P < 0.05), respectively (Figure 3A).

Live birth rate

Five studies (19, 27, 28, 31, 32) (n=785) reported the live birth rate, but these studies only included women with a history of miscarriages. The pooled results obtained using a fixed-effects model showed thatthe addition of LMWH to LDA did not improve the live birth rate (RR: 1.06, 95% CI: 0.96–1.16, P > 0.05) (Figure 3B).

Secondary outcomes

Placental abruption

We observed that the data from nine studies (19, 20, 22, 25– 29, 32) included (n = 1,464), the pooled results obtained using a fixed-effects model showed that the addition of LMWH to LDA did not reduced the risk of placental abruption (RR: 0.58, 95% CI: 0.33–1.02, P = 0.06). In the subgroup analysis, the addition of LMWH to LDA did not reduced the risk of placental abruptionin women with a history of PE (RR: 0.96, 95% CI: 0.45–2.05, P = 0.91). Conversely, in women with a history of miscarriages, the addition of LMWH to LDA can reduce the risk of placental abruption (RR: 0.30, 95% CI: 0.12-0.77, P = 0.01) (Figure 4A).

TABLE 1 Baseline characteristics of included studies in the meta-analysis.

Karadag et al. (19) A randomized controlled trial patients with factor V iolen mutation 59 Encaparin 40 mg/d + an 100 Before termination of mg/d Karadag et al. (19) A randomized controlled trial Recurrent pregnancy los patients with factor V iolen mutation 51 A5A 100 mg/d 250weeks Groom et al. (20) A multicenter open label randomized controlled trial With a history of gestational thormboyhlia 71 A5A 100 mg/d 250weeks Itoom et al. (21) A multicenter randomized controlled trial With a history of gestational typertension, gg. 71 A5A 100 mg/d 250weeks Itoom et al. (21) A multicenter randomized controlled trial With a history of gestational trial 16 Daltparin 500 iu/d + as mg/d Before termination of mg/d Pregnancy Itadud et al. (22) A multicenter randomized controlled trial With a history of ape 12 A5A 100 mg/d 250 weeks Itadud et al. (23) A multicenter randomized controlled trial With a history of ape 12 A5A 100 mg/d 250 weeks Itadud et al. (24) A open label randomized controlled trial With a history of pre (gr. 12 A5A 100 mg/d 250 weeks Itadual et al. (25) A nopen randomized clinical recut et al. (26) <	Study	Research design	Participant condition	No.	Interventions and dose	Duration of treatment (weeks)
matrixininitiaA shalo migidSecond and a share of the prepanary loss mg/dSecond a share of the prepanary mg/dSecond a share of the prepanary mg/dS	Karadag et al. (19)	A randomized controlled trial	Recurrent pregnancy loss	59	Enoxaparin 40 mg/d+asa 100	Before termination of
Karadag et al. (19) A randomized controlled trial Recurrent pregnancy loss patients with factor vielden mattation 59 Enocaparin 40 mg/d + as 100 Before termination of pregnancy Green et al. (20) A multicenter open label randomized controlled trial With a history of gestational hypertension, gg. 72 Enocaparin 4000 iu/d + as Broot etermination of pregnancy Before termination of pregnancy Horston et al. (21) A multicenter andomized controlled trial With a history of gestational hypertension, gg. 16 Ask bl mg/d ≤36 weeks Laddad et al. (22) A multicenter andomized controlled trial With a history of ges 12 Enocaparin 4000 iu/d + as mg/d Schore termination of pregnancy Laddad et al. (22) A multicenter andomized With a history of ges 12 Schore termination of mg/d Schore termination of mg/d Schore termination of mg/d Laddad et al. (23) A multicenter andomized With a history of ges 12 Schore termination of mg/d Schore termination of mg/d Schore termination of mg/d Laddad et al. (23) A open habel randomized With a history of ges (Gg. Schore termination of mg/d Schore termination of mg/d Schore termination of mg/d Laddad et al. (23) A open randomized (Ladine) A history of ges (Gg.			*		mg/d	pregnancy
gatema with factor vielder mutation mg/d gregancy Groom et al. (20) A multicenter open label randomized controlled trial With a history of gestational hypertension, fig. dirombophilia 72 Kan 100 mg/d ≤360 webs Hourn et al. (21) A multicenter randomized controlled trial With a history of gestational 16 Moltgarin 5,000 iu/d+ass Before termination of mg/d Haddal et al. (22) A multicenter randomized With a history of spect 12 Kan 00 mg/d ≤360 webs Haddal et al. (23) A multicenter randomized With a history of spec 12 Kan 00 mg/d ≤360 webs Haddal et al. (23) A multicenter randomized With a history of spec 12 Kan 00 mg/d 2360 webs Carl et al. (23) A open label randomized With a history of spec 43 Dalteparin 5,000 iu/d+asa Before termination of mg/d 190 mg/d 2360 webs Carl et al. (23) An open randomized limital A history of there or more controlled trial 16 A Ka N Img/d 35 webs Gris et al. (25) A monocentric, randomized trial Mith a history of ges (gr, trial 12 ASA N Img/d 35 weeb				61	ASA 100 mg/d	\leq 36weeks
Branch and Park 1 For any and only a solution of the program of the pro	Karadag et al. (19)	A randomized controlled trial	Recurrent pregnancy loss	59	Enoxaparin 40 mg/d+asa 100	Before termination of
Groom et al. (20) A multicenter open label randomized controlled trial With a history of gestational hypertension, fig. thrombophila 72 Broazpain 4.000 iu/d+aa Pregnancy Hoor et al. (21) A multicentre randomized controlled trial With a history of gestational hypertension, sga 76 ASA 100 mg/d 256 weeks Haddad et al. (22) A multicentre randomized controlled trial With a history of spe 120 ASA 50 mg/d 256 weeks Haddad et al. (22) A multicentre randomized controlled trial With a history of spe 122 Rozaparin 4.000 iu/d+aa Before termination of mg/d 256 weeks Carl et al. (23) A open label randomized controlled trial With a history of spe 122 ASA 10 mg/d 256 weeks Carl et al. (23) A open nabel randomized controlled trial With a history of here or more consecutive abortions and mg/d 256 weeks 250 weeks Hanabashi et al. An open randomized clinical placental hypertension, fig. mg/d ASA 81 mg/d 250 weeks Gris et al. (25) A monocentric, randomized controlled study With history of neg. placental hypertension, fig. placental 122 ASA 00 mg/d 260 weeks Gris et al. (25) A multicentre randomized controlled trial With history of recurrent abort			*		mg/d	pregnancy
randomized currolled rial hypertension fig. thrombophila 100 mg/d gengancy Hoom et al. (21) A multicentre randomized controlled trial With a history of gestational hypertension, sga 16 ASA 100 mg/d ≤56 weeks Haddad et al. (22) A multicentre randomized controlled trial With a history of gest at 100 mg/d 256 weeks 160 mg/d 256 weeks Haddad et al. (22) A multicentre randomized controlled trial With a history of a test two 45 ASA 100 mg/d 256 weeks Carl et al. (23) A open label randomized controlled trial With a history of a test two 45 ASA 100 mg/d 256 weeks Carl et al. (23) A open label randomized controlled trial A history of three or more controlled trial 75 ASA 100 mg/d 258 weeks Carl et al. (23) A monomentric, randomized controlled study A history of three or more placental abruption. 75 ASA 100 mg/d 258 weeks Carl et al. (25) A monomentric, randomized controlled study Nith a history of pg. gg. placental abruption. 112 ASA 100 mg/d 86 fore termination of mg/d Visse et al. (25) A multicentre randomized controlled trial With history of recurrent abruito, but to thrombophila 63 Roso mg/d 86 fore termination of mg/d Visse et al. (26) A multicentre randomized controlled trial				54	Enoxaparin 40 mg/d	≤36weeks
Hiombophila 77 ASA 100 mg/d 36 weeks Hiombophila 77 ASA 100 mg/d 36 weeks Hiombo et al. (21) A multicentre randomized controlled trial 1997 A multicentre randomized Program. Haddad et al. (22) A multicentre randomized Program. Haddad et al. (23) A open label randomized Program. Controlled trial 1977 A SA 100 mg/d 26 weeks Carl et al. (23) A open label randomized Program. Controlled trial 1977 A SA 100 mg/d 26 weeks Carl et al. (23) A open label randomized Program. Carl et al. (24) A open label randomized Program. Carl et al. (25) A open label randomized Program. Carl et al. (26) A open label randomized Program. Carl et al. (26) A open label randomized Program. Carl et al. (27) A open label randomized Program. Carl et al. (28) A open label randomized Program. Carl et al. (29) A open randomized Program. Carl et al. (20) A monocentric, randomized Program. Carl et al. (20) A monocentric, randomized Program. Prog	Groom et al. (20)	A multicenter open label	With a history of gestational	72	Enoxaparin 4,000 iu/d+asa	Before termination of
Hoorn et al. (21) A multicentre randomized controlled trial With a history of gestational history of gestational 16 Dateparin 5,000 iu/4+asa 80 Fore remination of mg/d Haddad et al. (22) A multicentre randomized controlled trial With a history of spe 122 Kosa 00 mg/d Solveeks Carl et al. (23) A ogen label randomized controlled trial With a history of at least two consecutive abortions and thrombosis 122 Kosa 100 mg/d Solveeks Emahashi et al. (24) A nopen randomized clinical trial A history of the cor more consecutive abortions and thrombosis 13 A Ka 81 mg/d ≤35 weeks Gris et al. (23) A monocentric, randomized controlled study A history of pr. fgr, placental abruption. 75 Kosa 27 mg/d Fore termination of pregnancy (24) Trial A monocentric, randomized controlled study With a history of gestational thrombophila 75 Kosa 100 mg/d Solveeks (24) A multicentre randomized controlled study Piecental abruption. 120 ASA 80 mg/d Solveeks (24) A multicentre randomized controlled trial With a history of gestational abruption, brup 76 Machagent abruption Solveeks (24) A multicentre randomized controlled trial <td></td> <td>randomized controlled trial</td> <td></td> <td></td> <td>100 mg/d</td> <td>pregnancy</td>		randomized controlled trial			100 mg/d	pregnancy
controlled trial hypertension, sa mg/d pregnancy Haddad et al. (22) A multicentre randomized controlled trial his history of spe 12 Kaka 0 mg/d Before termination of pregnancy Carl et al. (23) A open label randomized controlled trial With a history of at least two conscribe abortions and thrombosis 45 Dalteparin 5,000 in/d+asa 81 Before termination of mg/d Before termination of pregnancy Carl et al. (23) A open label randomized controlled trial With a history of three or more thrombosis 75 Enoxaparin 4,000 in/d+asa 81 Before termination of mg/d Carl et al. (23) A no open randomized clinical trian A history ofthree or more controlled study 75 Enoxaparin 4,000 in/d+asa 81 49 Carl et al. (25) A monocentric, randomized controlled study Mith a history of p. fgr, placental abortion. 112 Roxaparin 4,000 in/d+asa 81 Fereprancy Carl et al. (26) A multicentre randomized controlled trial With a history of recurrent hypertension, fgr, thrombophila 121 Roxaparin 4,000 in/d+asa Before termination of mg/d 160 56 Visser et al. (27) A multicentre randomized controlled trial With a history of recurrent hypertension, fgr, thrombophila Mitory of the core mg/d S6 S6 Kaandorp et al. (28) A multicentre randomized controlled trial				77	ASA 100 mg/d	\leq 36 weeks
HandbackHandbackHandbackSake or geneSake	Hoorn et al. (21)		, 0	16	*	
Haddad et al. (22) A multicentre randomized controlled trial With a history of spe 122 A noperin 4.000 iu/d+asa Refore termination of pregnancy 22 A A lop of label randomized controlled trial With a history of at least two consecutive abortions and thrombosis 122 A SA 100 mg/d 36 weeks 24 A nopen randomized clinical trial A history of three or more 13 ASA 81 mg/d 55 weeks 241 Trial A nonocentric, randomized clinical trial A history of pe, fgr, trial 12 Ronzaparin 4.000 iu/d+asa Refore termination of mg/d 241 Trial A nonocentric, randomized controlled study With a history of pe, fgr, thrombophilia 12 Ronzaparin 4.000 iu/d+asa Refore termination of pregnancy 247 A multicentre randomized controlled trial With a history of gestational hypertension, fgr, thrombophilia 75 A SA 10 mg/d 23 weeks 247 A multicentre randomized controlled trial With a history of recurrent abortion, but no controlled trial Not history of precurrent abortion, but no tormobphilia As No mg/d 23 weeks 24 A multicentre randomized controlled trial Had a history of necephiline recurrent miscarriage and were termination of recurrent miscarriage and were terempingto concureic or were termpingto concureic or were			71	16	-	
Carl et al. (23)A open label randomized controlled trialWith a history of at least two consecutive abortions and thrombosis122ASA 100 mg/d≤56 weeksCarl et al. (23)A open randomized clinical trialMith a history of at least two consecutive abortions and thrombosis45Daleparin 5,000 iu/d+asa 81Before termination of mg/dElmahashi et al.An open randomized clinical trialA history offhree or more consecutive miscarriages.75Enoxaparin 4,000 iu/day +asa to more to more to more to more to more to more to more controlled study45MeeksCarl et al. (25)A monocentric, randomized controlled studyWith a history of ge, fgr, thrombophilia112ASA 100 mg/d86 fore termination of pregnancyVises et al. (26)A multicentre randomized controlled trialWith a history of gestational hypertension, fgr, thrombophilia70Dalteparin 5,000 iu/d+asa to mg/dBefore termination of pregnancyVises et al. (27)A multicentre randomized controlled trialWith a history of recurrent abortion, but no thrombophilia69ASA 100 mg/d<36 weeks	Haddad et al. (22)		With a history of spe	122	Enoxaparin 4,000 iu/d+asa	Before termination of
Call et al. (23) A open label randomized controlled trial With a history of at least two consecutive abortions and thrombosis 45 Dalteparin 5.000 in/4+as 81 Before termination of mg/d Perogram Elmahashi et al. An open randomized clinical A history of three or more consecutive miscarriages. 43 A SA 81 mg/d ≤35weeks [24] trial Consecutive miscarriages. 75 Encotaparin 4.000 in/4-as 81 Pefore termination of palcental abruption. [24] trial Consecutive miscarriages. 75 A SA 81 mg/d Seconsecutive miscarriages. [24] trial Consecutive miscarriages. 75 A consequent Abruption. Seconsecutive miscarriages. [24] trial A monocentric, randomized With a history of pc, fgr, palcental abruption. 112 Rotaparin 4.000 iu/d+asa Pefore termination of 100 mg/d Perogram Vries et al. (26) A multicentre randomized controlled trial With a history of recurrent 70 Dalteparin 5.000 iu/d+asa Pefore termination of mg/d Perogram Visser et al. (27) A multicentre randomized controlled trial With a history of recurrent 76 ASA 100 mg/d Sa 50 weeks Kanandor et al. (28) A multicentre randomiz				122	0	
Link controlled trialconsecutive abortions and thrombosismg/dpregnancyElmahashi et al. (24)An open randomized clinical trialA history ofthree or more consecutive miscarriages.43ASA 81 mg/d≤35weeks(24)An open randomized clinical trialA history ofthree or more consecutive miscarriages.75Enoxaparin 4.000 iu/day +asa Tom g/d34 weeks(24)TailA monocentric, randomized controlled studyWith a history of pe, fgr, placental abruption.112Enoxaparin 4.000 iu/d+asa pregnancyBefore termination of pregnancyVries et al. (25)A multicentre randomized controlled trialWith a history of gestational hypertension, fgr, thrombophilia70Dalteparin 5.000 iu/d+asa pregnancyBefore termination of pregnancyVisser et al. (27)A multicentre randomized controlled trialWith a history of recurrent abortion, but no thrombophilia63enoxaparin 40 mg/d +asa pregnancyBefore termination of pregnancyKaandorp et al. (28)A multicentre randomized controlled trialWith a history of necurrent abortion, but no thrombophilia76ASA 80 ng/d≤35 weeksKaandorp et al. (28)A multicentre randomized controlled trialHad a history of unexplained were attemptingto conceive or were less than 6 weeks pregnant120ASA 80 ng/d≤35 weeksGris JC et al. (29)A monocentric, randomized controlled studyHad history of an unexplained pregnancy loss uiright first intended pregnancySi weeks630Enoxaparin 4.000 iu/day +as	Carl et al. (23)	A open label randomized	With a history of at least two		e e	—
Elmahashi et al. (24) An open randomized clinical trial A history ofhree or more consecutive miscarriages. 75 Boxaparin 4,000 iu/day+ase 75 m/d. Meeks Gris et al. (25) A monocentric, randomized controlled study With a history of pe, fgr, peacetal abruption. 112 Boxaparin 4,000 iu/da+ase 100 m/d Mefore termination of pregnancy Viris et al. (26) A multicentre randomized controlled trial With a history of gestational history of gestational 70 Daleparin 5,000 iu/dase 100 m/d Before termination of pregnancy Viris et al. (26) A multicentre randomized controlled trial With a history of gestational history of recurrent abrotion, but no controlled trial Nith a history of recurrent abrotion, but no controlled trial Af Mong/d Safore termination of pregnancy Kaandorp et al. (27) A multicentre randomized controlled trial Had history of necurrent abrotion, but no controlled trial Af a history of necurent abrotion, but no controlled trial Af a history of necurent abrotion, but no controlled trial Safore termination of pregnancy Kaandorp et al. (28) A multicentre randomized controlled trial Had history of necuplatent mercurent miscarriage and were attemptingto conceive or were less than 6 weeks mg/a Safore termination of pregnancy Gris (L21) Anonocentric, randomized controlled study Had history of necuplatent mercurent hiscarriage and were attemptingto conceive or were less than 6 weeks Mices Safoweeks		*	consecutive abortions and		*	
Elmahashi et al. An open randomized clinical A history offhree or more 75 Encoarparin 4.000 iu/day +aa 34 weeks (24) trial consecutive miscarriages. 75 mg/d For ASA 70 mg/d For ASA 100 mg/d For ASA 100 mg/d For ASA 100 mg/d For ASA 100 mg/d For ASA 80 mg			linoinoosis	43	ASA 81 mg/d	<35weeks
(24) trial consecutive miscarriages. 75 mg/d (75) ASA 100 mg/d Before termination of (75) Dateparin 4,000 iu/d+asa Before termination of (75) ASA 100 mg/d ≤36 weeks (75) ASA 100 mg/d gregnancy (75) Multicentre randomized With a history of gestational 70 Dateparin 5,000 iu/d+asa 80 Before termination of (75) Multicentre randomized With a history of recurrent 63 enoxaparin 40 mg/d+asa Before termination of (75) Asal 100mg/d gregnancy ithrombophilia ithrombophilia ithrombophilia (76) Asal 100mg/d sefore termination of mg/d gregnancy ithrombophilia (76) Asal 100mg/d sefore termination of m	Elmahashi et al	An open randomized clinical	A history offbree or more		Č,	—
Gris et al. (25) A monocentric, randomized controlled study With a history of pe, fgr, placental abruption. 112 Enoxaparin 4,000 iu/d+asa 100 mg/d Before termination of pregnancy Vries et al. (26) A multicentre randomized controlled trial With a history of gestational hypertension, fgr, thrombophilia 70 Dalteparin 5,000 iu/d+asa 80 Before termination of mg/d Vries et al. (27) A multicentre randomized controlled trial With a history of gestational hypertension, fgr, thrombophilia 69 ASA 80 mg/d ≤36weeks Visser et al. (27) A multicentre randomized controlled trial With a history of recurrent abortion, but no thrombophilia 63 enoxaparin 40 mg/d+asa 100mg/d Before termination of pregnancy Kaandorp et al. (28) A multicentre randomized controlled trial Had a history of unexplained recurrent miscarriage and were attemptingto conceive or were less than 6 weeks pregnant ASA 80 ng/d ≤35 weeks Gris JC et al. (29) A monocentric, randomized controlled study Had a history of an unexplained pregnancy loss during the first intended pregnancy 80 Enoxaparin 4,000 iu/day +asa 100 mg/d 56weeks		<u>^</u>		,,,,		
Gris et al. (25)A monocentric, randomized controlled studyWith a history of pe, fgr, placental abruption.112Enoxaparin 4,000 iu/d+asa 100 mg/dBefore termination of pregnancyVries et al. (26)A multicentre randomized controlled trialWith a history of gestational hypertension, fgr, thrombophilia70Dalteparin 5,000 iu/d+asa 80Before termination of mg/dVisser et al. (27)A multicentre randomized controlled trialWith a history of recurrent abortion, but no thrombophilia63enoxaparin 40 mg/d+asa mg/dBefore termination of pregnancyKaandorp et al. (28)A multicentre randomized controlled trialWith a history of necurrent abortion, but no thrombophilia63enoxaparin 40 mg/d+asa (100 mg/d)Before termination of pregnancyKaandorp et al. (28)A multicentre randomized controlled trialHad a history of unexplained mercurent miscarriage and were attemptingto conceive or were less than 6 weeks pregnant76ASA 100mg/d≤35 weeksGris JC et al. (29)A monocentric, randomized controlled studyHad a history of an unexplained pregnancy loss during the first intended pregnancy80Enoxaparin 4,000 iu/day +asa (100 mg/d)36 weeks			Ŭ	75	-	
Vries et al. (26) A multicentre randomized controlled trial With a history of gestational hypertension, fgr, thrombophilia 70 Dalteparin 5,000 iu/d+asa 80 Before termination of mg/d Visser et al. (27) A multicentre randomized controlled trial With a history of recurrent abortion, but no thrombophilia 63 enoxaparin 40 mg/d +asa Before termination of mg/d Kaandorp et al. (28) A multicentre randomized controlled trial With a history of recurrent abortion, but no thrombophilia 63 enoxaparin 40 mg/d +asa Before termination of pregnancy Kaandorp et al. (28) A multicentre randomized controlled trial Had a history of unexplained recurrent miscarriage and were attempting to conceive or were less than 6 weeks pregnant 123 nadroparin 2850 iu/d +asa 80 Before termination of mg/d Gris JC et al. (29) A monocentric, randomized controlled study Had a history of an unexplained pregnancy loss during the first intended pregnancy 80 Enoxaparin 4,000 iu/day +asa 100 mg/d 36 weeks	Gris et al. (<mark>25</mark>)	A monocentric, randomized	With a history of pe, fgr,	112	Enoxaparin 4,000 iu/d+asa	Before termination of
Vries et al. (26) A multicentre randomized controlled trial With a history of gestational hypertension, fgr, thrombophilia 70 Dalteparin 5,000 iu/d+asa 80 Before termination of mg/d Visser et al. (27) A multicentre randomized controlled trial With a history of recurrent abortion, but no thrombophilia 69 ASA 80 mg/d ≤36weeks Kaandorp et al. (28) A multicentre randomized controlled trial With a history of necurrent abortion, but no 63 enoxaparin 40 mg/d+asa Before termination of pregnancy Kaandorp et al. (28) A multicentre randomized controlled trial Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of pregnancy Gris JC et al. (29) A monocentric, randomized controlled study Had a history of an unexplained pregnancy loss during the first intended pregnancy 80 Enoxaparin 4,000 iu/d+asa 86/ore termination of pregnancy		controlled study	placental abruption.		100 mg/d	pregnancy
controlled trial hypertension, fgr, thrombophilia mg/d pregnancy Visser et al. (27) A multicentre randomized With a history of recurrent 63 enoxaparin 40 mg/d+asa Before termination of Visser et al. (27) A multicentre randomized With a history of recurrent 63 enoxaparin 40 mg/d+asa Before termination of kaandorp et al. (28) A multicentre randomized Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of kaandorp et al. (28) A multicentre randomized Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of kaandorp et al. (28) A multicentre randomized Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of kaandorp et al. (28) A multicentre randomized Had a history of an weeks mg/d secontrolled trial Secontrolled t				112	ASA 100 mg/d	\leq 36 weeks
Kince in the intrombophilia 69 ASA 80 mg/d ≤36weeks Visser et al. (27) A multicentre randomized controlled trial With a history of recurrent abortion, but no 63 enoxaparin 40 mg/d+asa Before termination of pregnancy Kaandorp et al. (28) A multicentre randomized controlled trial Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of mg/d Kaandorp et al. (28) A multicentre randomized Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of mg/d Kaandorp et al. (28) A multicentre randomized Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of mg/d Kaandorp et al. (28) A multicentre randomized Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of mg/d Kaandorp et al. (28) A monocentric, randomized Had a history of an mg/d 120 ASA 80 mg/d ≤36weeks Gris JC et al. (29) A monocentric, randomized Had a history of an mg/d 80 Enoxaparin 4,000 iu/day +asa 36 weeks unexplained pregnancy loss unexplained pregnancy loss 100 mg/d 100 mg/d 100 mg/d	Vries et al. (<mark>26</mark>)	A multicentre randomized	With a history of gestational	70	Dalteparin 5,000 iu/d+asa 80	Before termination of
Visser et al. (27) A multicentre randomized With a history of recurrent 63 enoxaparin 40 mg/d+asa Before termination of 100mg/d pregnancy brows before termination of 100mg/d study before termination of 100mg/d study before termination of 100mg/d study before termination of 123 market before terminatin termination of 123 market before terminatin terminatin term		controlled trial	71 U		mg/d	pregnancy
controlled trial abortion, but no 100mg/d pregnancy thrombophilia 76 ASA 100mg/d ≤35 weeks Kaandorp et al. (28) A multicentre randomized Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of controlled trial recurrent miscarriage and mg/d pregnancy were attemptingto conceive or were less than 6 weeks pregnant second second for JC et al. (29) A monocentric, randomized Had a history of an 80 Enoxaparin 4,000 iu/day +asa 36 weeks Gris JC et al. (29) A monocentric, randomized Had a history of an 80 Enoxaparin 4,000 iu/day +asa 36 weeks unexplained pregnancy loss unexplained pregnancy loss 100 mg/d second second second gring the first intended pregnancy second second second second second gring the first intended pregnancy second second second second second				69	ASA 80 mg/d	≤36weeks
thrombophilia Kaandorp et al. (28) A multicentre randomized controlled trial Had a history of unexplained 123 nadroparin 2850 iu/d +asa 80 Before termination of recurrent miscarriage and mg/d pregnancy were attemptingto conceive or were less than 6 weeks pregnant	Visser et al. (27)	A multicentre randomized	With a history of recurrent	63	enoxaparin 40 mg/d+asa	Before termination of
Kaandorp et al. (28)A multicentre randomized controlled trialHad a history of unexplained recurrent miscarriage and were attemptingto conceive or were less than 6 weeks pregnant76ASA 100mg/d≤35 weeksGris JC et al. (29)A monocentric, randomized controlled studyHad a history of an unexplained pregnancy loss during the first intended pregnancy80Enoxaparin 4,000 iu/day +asa 100 mg/d36 weeks		controlled trial	abortion, but no		100mg/d	pregnancy
Kaandorp et al. (28)A multicentre randomized controlled trialHad a history of unexplained recurrent miscarriage and were attemptingto conceive or were less than 6 weeks pregnant123nadroparin 2850 iu/d +asa 80Before termination of mg/dGris JC et al. (29)A monocentric, randomized controlled studyHad a history of an unexplained pregnancy loss during the first intended pregnancy80Enoxaparin 4,000 iu/day +asa 100 mg/d36 weeks			thrombophilia			
controlled trial recurrent miscarriage and mg/d pregnancy were attemptingto conceive or were less than 6 weeks pregnant Gris JC et al. (29) A monocentric, randomized Had a history of an 80 Enoxaparin 4,000 iu/day +asa 36 weeks controlled study unexplained pregnancy loss 100 mg/d during the first intended pregnancy				76	ASA 100mg/d	\leq 35 weeks
were attemptingto conceive or were less than 6 weeks pregnant Gris JC et al. (29) A monocentric, randomized Had a history of an 80 Enoxaparin 4,000 iu/day +asa 36 weeks controlled study unexplained pregnancy loss 100 mg/d during the first intended pregnancy	Kaandorp et al. (<mark>28</mark>)	A multicentre randomized	Had a history of unexplained	123	nadroparin 2850 iu/d +asa 80	Before termination of
were less than 6 weeks pregnant Gris JC et al. (29) A monocentric, randomized controlled study Had a history of an 80 Enoxaparin 4,000 iu/day +asa 36 weeks unexplained pregnancy loss 100 mg/d during the first intended pregnancy		controlled trial	recurrent miscarriage and		mg/d	pregnancy
pregnant Gris JC et al. (29) A monocentric, randomized Had a history of an 80 Enoxaparin 4,000 iu/day +asa 36 weeks controlled study unexplained pregnancy loss 100 mg/d during the first intended pregnancy			were attempting to conceive or			
Gris JC et al. (29) A monocentric, randomized Had a history of an 80 Enoxaparin 4,000 iu/day +asa 36 weeks controlled study unexplained pregnancy loss 100 mg/d 100 mg/d pregnancy First intended 100 mg/d 100 mg/d			were less than 6 weeks			
Gris JC et al. (29) A monocentric, randomized Had a history of an 80 Enoxaparin 4,000 iu/day +asa 36 weeks controlled study unexplained pregnancy loss 100 mg/d during the first intended pregnancy			pregnant			_
controlled study unexplained pregnancy loss 100 mg/d during the first intended pregnancy					Č,	
during the first intended pregnancy	Gris JC et al. (29)	•		80		36 weeks
pregnancy		controlled study			100 mg/d	
			-			
80 ASA 100 mg/d			pregnancy	00	ASA 100 mm/d	

(Continued)

TABLE 1	(Continued)
---------	-------------

Study	Research design	Participant condition	No.	Interventions and dose	Duration of treatment (weeks)
Sergio et al. (30)	A monocentric, randomized	With a history of pe, fgr, but	31	enoxaparin 4,000 iu/d+asa	Before termination of
	controlled study	no thrombophilia		100 mg/d	pregnancy
			23	ASA 100 mg/d	\leq 36 weeks
Goel et al. (31)	A randomized controlled trial	With a history of two or more	33	heparin 5,000 iu/d+asa 80	36 weeks
		spontaneousabortions		mg/d	
			39	ASA 80 mg/d	
Farquharson et al.	A randomized controlled trial	With a history of at least three	51	unspecified lmwh 5,000	36 weeks
(32)		consecutive pregnancy		iu/d+asa 75 mg/d	
		lossesor two consecutive			
		losses with proven fetal death			
		after 10weeks' gestation			
			47	ASA 75 mg/d	

SGA

Six studies (20, 22, 23, 25, 28, 30) (n = 889) reported the SGA, the pooled results obtained using a fixed-effects model showed that the addition of LMWH to LDA reduced the the risk of SGA (RR: 0.71, 95% CI: 0.52–0.97, P = 0.03). But in the subgroup analysis, the addition of LMWH to LDA did not reduced the risk of SGA in women with a history of PE (RR: 0.73, 95% CI: 0.52–1.02, P = 0.07) and miscarriages (RR: 0.63, 95% CI: 0.28–1.42, P = 0.27), respectively (Figure 4B).

sPE

Four studies (20, 22, 25, 29) (n = 777) reported the sPE, the pooled results obtained using a random-effects model showed that the addition of LMWH to LDA did not reduced the the risk of sPE (RR: 0.46, 95% CI: 0.13–1.62, P = 0.23). In the subgroup analysis, the addition of LMWH to LDA did not reduced the risk of sPE in women with a history of PE (RR: 0.67, 95% CI: 0.17–2.60, P = 0.57). Conversely, in women with a history of miscarriages, the addition of LMWH to LDA can reduce the risk of sPE (RR: 0.17, 95% CI: 0.04–0.72, P = 0.02) (Figure 4C).

Gestational hypertension

Three studies (19–21) (n = 414) reported the gestational hypertension, the pooled results obtained using a fixed-effects model showed that the addition of LMWH to LDA reduced the the risk of gestational hypertension (RR: 0.47, 95% CI: 0.25–0.90, P = 0.02). In the subgroup analysis, the addition of LMWH to LDA did not reduced the risk of gestational hypertension in women with a history of PE (RR: 0.64, 95% CI: 0.32–1.29, P = 0.21). However, in women with a history of miscarriages, the addition of LMWH to LDA can reduce the risk of gestational hypertension (RR: 0.12, 95% CI: 0.02–0.96, P = 0.05) (Figure 4D).

FGR


Four studies (19, 21, 26, 27) (n = 491) reported the FGR, the pooled results obtained using a fixed-effects model showed that the addition of LMWH to LDA did not reduced the the risk of FGR (RR: 0.85, 95% CI: 0.54–1.34, P = 0.48). In the subgroup analysis, the addition of LMWH to LDA also did not reduced the risk of FGR in women with a history of PE (RR: 0.67, 95% CI: 0.38–1.21, P = 0.19) and miscarriages (RR: 1.17, 95% CI: 0.56–2.45, P = 0.67), respectively (Figure 4E).

Fetal and neonatal death

Nine studies (20–23, 25, 26, 28–30) (n = 1,220) reported the fetal and neonatal death, the pooled results obtained using a fixed-effects model showed that the addition of LMWH to LDA reduced the risk of fetal and neonatal death (RR: 0.45, 95% CI: 0.23–0.88, P = 0.02). In the subgroup analysis, the addition of LMWH to LDA also can reduced the risk of fetal and neonatal deathin women with a history of PE (RR: 0.41, 95% CI: 0.18– 0.92, P = 0.03), but the addition of LMWH to LDA did not reduce the risk of fetal and neonatal death in women with a history of miscarriages (RR: 0.55, 95% CI: 0.16–1.87, P = 0.34) (Figure 4F).

HELLP syndrome

Six studies (20–22, 25, 26, 28) (n = 918) reported the HELLP syndrome, the pooled results obtained using a fixedeffects model showed that the addition of LMWH to LDA did not obviously reduced the risk of HELLP syndrome (RR: 0.54, 95% CI: 0.22–1.33, P = 0.18). In the subgroup analysis, the addition of LMWH to LDA also did not reduced the risk of HELLP syndrome in women with a history of PE (RR: 0.57, 95% CI: 0.22–1.47, P = 0.25) and miscarriages (RR: 0.30, 95% CI: 0.01–7.12, P = 0.45), respectively. Although the results were



not statistically different, it can be seen from the Figure 4G that LDA combined with LMWH is more beneficial to prevent the occurrence of HELLP syndrome and is a more favorable treatment option (Figure 4G).

Safety outcomes

Intrapartum or postpartum hemorrhage

Three studies (25, 27, 29) (n = 471) reported the intrapartum or postpartum hemorrhage, the pooled results obtained using a fixed-effects model showed that the addition of LMWH to LDA did not increased the risk of intrapartum or postpartum hemorrhage (RR: 0.66, 95% CI: 0.34–1.26, P = 0.20) (Figure 5).

Publication bias

The results of Begg's and Egger's tests showed no evidence of publication bias for all the outcomes except PE, as all the results showed P > 0.05 (Table 2). However, there was evidence of publication bias for PE, as the *P*-value from Egger's tests was 0.007, the P value from Begg's tests was 0.02.


Discussion


The results of this systematic review and meta-analysas showed that among women with a history of PE, LMWH combined with LDA can effectively reduce the incidence of

	LMWH+A	ASA	ASA			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
history of PE							
Gris JC et al.2011	6	112	17	112	16.3%	0.35 [0.14, 0.86]	
Groom et al.2017	6	72	5	77	4.6%	1.28 [0.41, 4.02]	
Haddad et al.2016	22	122	27	122	25.9%	0.81 [0.49, 1.35]	
Hoorn et al.2016	0	16	2	16	2.4%	0.20 [0.01, 3.86]	
Sergio et al.2006	1	31	7	23	7.7%	0.11 [0.01, 0.80]	
Vries et al. 2011 Subtotal (95% CI)	11	70 423	15	69 419	14.5% 71.3%	0.72 [0.36, 1.46] 0.62 [0.45, 0.87]	•
Total events	46		73				
Heterogeneity: Chi ² = 7.8	85, df = 5 (F	P = 0.16)	; I ² = 36%	6			
Test for overall effect: Z	= 2.75 (P =	0.006)					
miscarriage							
Gris JC et al.2010	6	80	18	80	17.2%	0.33 [0.14, 0.80]	_ _
Kaandorp et al.2010	2	69	1	61	1.0%	1.77 [0.16, 19.02]	
Karadağ et al. 2019	3	59	8	61	7.5%	0.39 [0.11, 1.39]	
Karadağ et al. 2019(2)	3	59	2	54	2.0%	1.37 [0.24, 7.91]	
Visser et al. 2011	1	41	1	46	0.9%	1.12 [0.07, 17.37]	· · · ·
Subtotal (95% CI)		308		302	28.7%	0.50 [0.27, 0.90]	•
Total events	15		30				
Heterogeneity: Chi ² = 3.0	68, df = 4 (F	P = 0.45)	; I ² = 0%				
Test for overall effect: Z	= 2.31 (P =	0.02)					
Total (95% CI)		731		721	100.0%	0.59 [0.44, 0.79]	◆
Total (95% CI) Total events	61	731	103	721	100.0%	0.59 [0.44, 0.79]	•
					100.0%	0.59 [0.44, 0.79]	▲
Total events Heterogeneity: Chi² = 12 Test for overall effect: Z	2.24, df = 10 = 3.56 (P =	(P = 0.2 0.0004)	27); l² = 1	8%		0.59 [0.44, 0.79]	
Total events Heterogeneity: Chi ² = 12	2.24, df = 10 = 3.56 (P =	(P = 0.2 0.0004)	27); l² = 1	8%		0.59 [0.44, 0.79]	0.01 0.1 1 10 100 Favours [LMWH+ASA] Favours [ASA]
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe	2.24, df = 10 = 3.56 (P =	(P = 0.2 0.0004)	27); l² = 1	8%		0.59 [0.44, 0.79]	
Total events Heterogeneity: Chi² = 12 Test for overall effect: Z	2.24, df = 10 = 3.56 (P =	(P = 0.2 0.0004) = 0.43, c	27); l² = 1	8% = 0.51)		0.59 [0.44, 0.79] Risk Ratio	
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe	2.24, df = 10 = 3.56 (P = ences: Chi ² =	(P = 0.2 0.0004) = 0.43, c	27); l ² = 1 If = 1 (P = Contr	8% = 0.51) rol			Favours [LMWH+ASA] Favours [ASA]
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe live birth rate	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experime	(P = 0.2 0.0004) = 0.43, c	27); l ² = 1 If = 1 (P = Contr	8% = 0.51) rol	, I² = 0%	Risk Ratio	Favours [LMWH+ASA] Favours [ASA]
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe live birth rate Study or Subgroup	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experime Events	(P = 0.2 0.0004) = 0.43, c ental Total	27); I ² = 1 If = 1 (P = Contr Events	8% = 0.51) rol Total	, l² = 0% Weight	Risk Ratio M-H, Fixed, 95% Cl	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe blive birth rate Study or Subgroup Farguharson et al.2002	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experim Events 40	(P = 0.2 0.0004) = 0.43, c ental <u>Total</u> 51	27); I ² = 1 df = 1 (P = Contr <u>Events</u> 34	8% = 0.51) rol <u>Total</u> 47	, l² = 0% <u>Weight</u> 14.4%	Risk Ratio <u>M-H, Fixed, 95% Cl</u> 1.08 [0.86, 1.36]	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe live birth rate Study or Subgroup Farquharson et al.2002 Goel et al.2006	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experim Events 40 28	(P = 0.2) (0.0004) = 0.43, contract ental Total 51 33	27); ² = 1 if = 1 (P = <u>Contr</u> <u>Events</u> 34 24	8% = 0.51) rol <u>Total</u> 47 39	, I ² = 0% <u>Weight</u> 14.4% 9.0%	Risk Ratio <u>M-H, Fixed, 95% Cl</u> 1.08 [0.86, 1.36] 1.38 [1.03, 1.84]	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe Live birth rate Study or Subgroup Farquharson et al.2002 Goel et al.2006 Kaandorp et al.2010	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experim Events 40 28 67 51 51	ental 51 51 51 52 51 53 123	27); ² = 1 if = 1 (P = <u>Contr</u> <u>Events</u> 34 24 61	8% = 0.51) rol <u>Total</u> 47 39 120	, l ² = 0% Weight 14.4% 9.0% 25.2%	Risk Ratio <u>M-H, Fixed, 95% Cl</u> 1.08 [0.86, 1.36] 1.38 [1.03, 1.84] 1.07 [0.84, 1.36]	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe Live birth rate Study or Subgroup Farquharson et al.2002 Goel et al.2006 Kaandorp et al.2010 Karadağ et al. 2019	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experime Events 40 28 67 51	ental 51 33 123 59	27); l ² = 1 If = 1 (P = Contr Events 34 24 61 53	8% = 0.51) rol <u>Total</u> 47 39 120 61	, l ² = 0% Weight 14.4% 9.0% 25.2% 21.2%	Risk Ratio M-H, Fixed, 95% Cl 1.08 [0.86, 1.36] 1.38 [1.03, 1.84] 1.07 [0.84, 1.36] 0.99 [0.86, 1.14]	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe Live birth rate Study or Subgroup Farquharson et al.2002 Goel et al.2006 Kaandorp et al.2010 Karadağ et al. 2019 Karadağ et al. 2019(2)	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experim Events 40 28 67 51 51	ental 51 51 33 123 59 59	27); ² = 1 If = 1 (P = Contr <u>Events</u> 34 24 61 53 45	8% = 0.51) Total 47 39 120 61 54 76	, ² = 0% Weight 14.4% 9.0% 25.2% 21.2% 19.1%	Risk Ratio M-H, Fixed, 95% Cl 1.08 [0.86, 1.36] 1.38 [1.03, 1.84] 1.07 [0.84, 1.36] 0.99 [0.86, 1.14] 1.04 [0.89, 1.21]	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe Live birth rate <u>Study or Subgroup</u> Farquharson et al.2002 Goel et al.2006 Kaandorp et al.2010 Karadağ et al. 2019 Karadağ et al. 2019(2) Visser et al. 2011	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experim Events 40 28 67 51 51	ental Total 51 33 123 59 63	27); ² = 1 If = 1 (P = Contr <u>Events</u> 34 24 61 53 45	8% = 0.51) Total 47 39 120 61 54 76	Weight 14.4% 9.0% 25.2% 21.2% 19.1% 11.1%	Risk Ratio M-H, Fixed, 95% CI 1.08 [0.86, 1.36] 1.38 [1.03, 1.84] 1.07 [0.84, 1.36] 0.99 [0.86, 1.14] 1.04 [0.89, 1.21] 0.88 [0.57, 1.37]	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe Live birth rate <u>Study or Subgroup</u> Farquharson et al.2002 Goel et al.2006 Kaandorp et al.2010 Karadağ et al. 2019 Karadağ et al. 2019(2) Visser et al. 2011 Total (95% CI)	2.24, df = 10 = 3.56 (P = ences: Chi ² : Experime Events 40 28 67 51 51 22 259	ental 51 33 123 59 63 388	27); l ² = 1 If = 1 (P = Contr Events 34 24 61 53 45 30 247	8% = 0.51) Total 47 39 120 61 54 76	Weight 14.4% 9.0% 25.2% 21.2% 19.1% 11.1%	Risk Ratio M-H, Fixed, 95% CI 1.08 [0.86, 1.36] 1.38 [1.03, 1.84] 1.07 [0.84, 1.36] 0.99 [0.86, 1.14] 1.04 [0.89, 1.21] 0.88 [0.57, 1.37]	Favours [LMWH+ASA] Favours [ASA]
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe Live birth rate Study or Subgroup Farquharson et al.2002 Goel et al.2006 Kaandorp et al.2010 Karadağ et al. 2019 Karadağ et al. 2019(2) Visser et al. 2011 Total (95% CI) Total events Heterogeneity: Chi ² = 4.7	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experime Events 40 28 67 51 51 22 259 76, df = 5 (P	ental Total 51 33 123 59 63 388 = 0.45)	27); l ² = 1 If = 1 (P = Contr Events 34 24 61 53 45 30 247	8% = 0.51) Total 47 39 120 61 54 76	Weight 14.4% 9.0% 25.2% 21.2% 19.1% 11.1%	Risk Ratio M-H, Fixed, 95% CI 1.08 [0.86, 1.36] 1.38 [1.03, 1.84] 1.07 [0.84, 1.36] 0.99 [0.86, 1.14] 1.04 [0.89, 1.21] 0.88 [0.57, 1.37]	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Total events Heterogeneity: Chi ² = 12 Test for overall effect: Z Test for subgroup differe Live birth rate <u>Study or Subgroup</u> Farquharson et al.2002 Goel et al.2006 Kaandorp et al.2010 Karadağ et al. 2019 Karadağ et al. 2019(2) Visser et al. 2011 Total (95% CI) Total events	2.24, df = 10 = 3.56 (P = ences: Chi ² = Experime Events 40 28 67 51 51 22 259 76, df = 5 (P	ental Total 51 33 123 59 63 388 = 0.45)	27); l ² = 1 If = 1 (P = Contr Events 34 24 61 53 45 30 247	8% = 0.51) Total 47 39 120 61 54 76	Weight 14.4% 9.0% 25.2% 21.2% 19.1% 11.1%	Risk Ratio M-H, Fixed, 95% CI 1.08 [0.86, 1.36] 1.38 [1.03, 1.84] 1.07 [0.84, 1.36] 0.99 [0.86, 1.14] 1.04 [0.89, 1.21] 0.88 [0.57, 1.37]	Favours [LMWH+ASA] Favours [ASA]

PE and fetal and neonatal death. However, in the prevention of placental abruption, sPE, gestational hypertension, SGA and FGR, compared with LDA or LMWH alone, the combination of the drugs appeared to have no benefit. Nevertheless, the combination of drugs reduced the incidence of gestational hypertension, sPE, SGA and FGR in women who had previously developed PE. In women with a history of miscarriage, LMWH combined with LDA can significantly reduce the incidence of PE, placental abruption, sPE and gestational hypertension. However, there was no significant difference between the combined use of the two drugs and the use of a single drug in improving the live birth rate of fetus and reducing the incidence of SGA, FRG and fetal and neonatal death. Despite the results, the combination of drugs increased the number of newborns and decreased the number of SGA and fetal and neonatal death in women with previous miscarriages. In addition, no major side effects such as intrapartum or postpartum hemorrhage were observed in women treated with LMWH combined with LDA, and the combined medication reduced the incidence of HELLP syndrome.

During our search in the above mentioned databases, we found a meta-analysis (8) reported on LMWH combined with aspirin in preventing PE and SGA. The meta-analysis involved 8 RCTs, which were divided into two subgroups according to





	Experime		Contr			Risk Ratio	Risk Ratio
Study or Subgroup	Events	lotal	Events	lotal	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
history of PE	2	110	0	110	00 70/	0 50 10 42 4 051	
Gris JC et al.2011	3	112	6	112	22.7%	0.50 [0.13, 1.95]	
Groom et al.2017	2	72	3	77	11.0%	0.71 [0.12, 4.14]	
Haddad et al.2016	1	122	4	122	15.1%	0.25 [0.03, 2.20]	
Hoorn et al.2016	0 1	16	0	16	12 00/	Not estimable	
Sergio et al.2006		31	3	23	13.0%	0.25 [0.03, 2.23]	
Vries et al. 2011 Subtotal (95% CI)	1	70 423	3	69 419	11.4% 73.3%	0.33 [0.04, 3.08] 0.41 [0.18, 0.92]	
Total events	8		19				
Heterogeneity: Chi ² = (Test for overall effect: 2		•		%			
miscarriage							
Carl A. et al. 2014	0	45	1	43	5.8%	0.32 [0.01, 7.62]	
Gris JC et al.2010	2	80	5	80	18.9%	0.40 [0.08, 2.00]	
Kaandorp et al.2010	1	69	0	61	2.0%	2.66 [0.11, 64.04]	
Subtotal (95% CI)		194		184	26.7%	0.55 [0.16, 1.87]	
Total events	3		6				
Heterogeneity: Chi ² = 1 Test for overall effect: 2		•		%			
Total (95% CI)		617		603	100.0%	0.45 [0.23, 0.88]	•
Total events	11		25				
Heterogeneity: Chi ² = 2	2.19, df = 7 ((P = 0.9)	95); I ² = 0 ⁴	%			0.01 0.1 1 10 100
		- 0.001					0.01 0.1 1 10 100
Test for overall effect: 2	rences: Chi ²	,		P = 0.6	9), l² = 0%		Favours [LMWH+ASA] Favours [ASA]
	rences: Chi ²	2 = 0.16			9), I ² = 0%	Risk Ratio	Favours [LMWH+ASA] Favours [ASA] Risk Ratio
Test for subgroup diffe	rences: Chi ^a e	² = 0.16	6, df = 1 (F Contr	ol	9), I ² = 0% Weight		Risk Ratio
Test for subgroup diffe	rences: Chi ^a e Experime	² = 0.16	6, df = 1 (F Contr	ol		Risk Ratio	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup	rences: Chi ^a e Experime	² = 0.16	6, df = 1 (F Contr	ol		Risk Ratio	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE	rences: Chi ^a e Experime Events	² = 0.16 ntal Total	6, df = 1 (F Contro Events	ol Total	Weight	Risk Ratio M-H, Fixed, 95% Cl	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011	e Experime Events 1	² = 0.16 ntal <u>Total</u> 112	6, df = 1 (F Contre Events 3	ol <u>Total</u> 112	Weight 23.0%	Risk Ratio <u>M-H, Fixed, 95% Cl</u> 0.33 [0.04, 3.16]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017	rences: Chi ^a Experime Events 1 1	² = 0.16 ntal <u>Total</u> 112 72	6, df = 1 (F Contr <u>Events</u> 3 2	ol <u>Total</u> 112 77	Weight 23.0% 14.8%	Risk Ratio <u>M-H, Fixed, 95% Cl</u> 0.33 [0.04, 3.16] 0.53 [0.05, 5.77]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011	rences: Chi ^a Experime Events 1 1 2	ntal Total 112 122 16 70	6, df = 1 (F Contre Events 3 2 2 2	ol <u>Total</u> 112 77 122 16 69	Weight 23.0% 14.8% 15.3% 11.5% 23.2%	Risk Ratio M-H, Fixed, 95% CI 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016	e Experime Events 1 1 2 0	ntal Total 112 72 122 16	5, df = 1 (F Contre Events 3 2 2 1	ol <u>Total</u> 112 77 122 16	Weight 23.0% 14.8% 15.3% 11.5%	Risk Ratio M-H, Fixed, 95% Cl 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011	e Experime Events 1 1 2 0	ntal Total 112 122 16 70	5, df = 1 (F Contre Events 3 2 2 1	ol <u>Total</u> 112 77 122 16 69	Weight 23.0% 14.8% 15.3% 11.5% 23.2%	Risk Ratio M-H, Fixed, 95% CI 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI)	e Experime Events 1 1 2 0 2 6 0.68, df = 4	ntal Total 112 72 122 16 70 392 (P = 0.9	Contr Events 3 2 2 1 3 11 95); I ² = 0'	ol <u>Total</u> 112 77 122 16 69 396	Weight 23.0% 14.8% 15.3% 11.5% 23.2%	Risk Ratio M-H, Fixed, 95% CI 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0	e Experime Events 1 1 2 0 2 6 0.68, df = 4	ntal Total 112 72 122 16 70 392 (P = 0.9	Contr Events 3 2 2 1 3 11 95); I ² = 0'	ol <u>Total</u> 112 77 122 16 69 396	Weight 23.0% 14.8% 15.3% 11.5% 23.2%	Risk Ratio M-H, Fixed, 95% CI 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = (Test for overall effect: 2	e Experime Events 1 1 2 0 2 6 0.68, df = 4	ntal Total 112 72 122 16 70 392 (P = 0.9	Contr Events 3 2 2 1 3 11 95); I ² = 0'	ol <u>Total</u> 112 77 122 16 69 396	Weight 23.0% 14.8% 15.3% 11.5% 23.2%	Risk Ratio M-H, Fixed, 95% CI 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = (Test for overall effect: 3 miscarriage Kaandorp et al.2010 Subtotal (95% CI)	e Experime Events 1 1 2 0 2 6 0.68, df = 4 (Z = 1.16 (P	ntal Total 112 122 16 70 392 (P = 0.9) (P = 0	6, df = 1 (F Contr Events 3 2 2 1 3 11 95); I ² = 0 ²	ol Total 112 77 122 69 396 %	Weight 23.0% 14.8% 15.3% 11.5% 23.2% 87.8%	Risk Ratio M-H, Fixed, 95% Cl 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81] 0.57 [0.22, 1.47] 0.30 [0.01, 7.12]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = (Test for overall effect: 2 miscarriage Kaandorp et al.2010	e Experime Events 1 1 2 0 2 6 0.68, df = 4 Z = 1.16 (P 0 0 0 0	ntal Total 112 72 16 70 392 (P = 0.25) 69 69	S, df = 1 (F Contr Events 3 2 2 1 3 11 95); I ² = 0 ¹ 1 1	ol Total 112 77 122 69 396 %	Weight 23.0% 14.8% 15.3% 11.5% 23.2% 87.8%	Risk Ratio M-H, Fixed, 95% Cl 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81] 0.57 [0.22, 1.47] 0.30 [0.01, 7.12]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = (Test for overall effect: 2 miscarriage Kaandorp et al.2010 Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: 2	e Experime Events 1 1 2 0 2 6 0.68, df = 4 Z = 1.16 (P 0 0 0 0	ntal Total 112 72 16 70 392 (P = 0.25) 69 69	S, df = 1 (F Contr Events 3 2 2 1 3 11 95); I ² = 0 ¹ 1 1	ol <u>Total</u> 112 77 122 16 69 396 % 61 61	Weight 23.0% 14.8% 15.3% 11.5% 23.2% 87.8%	Risk Ratio M-H, Fixed, 95% Cl 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81] 0.57 [0.22, 1.47] 0.30 [0.01, 7.12]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = (Total events Heterogeneity: Not app Test for overall effect: 2 Total events Heterogeneity: Not app Test for overall effect: 2	e Experime Events 1 1 2 0 2 6 0.68, df = 4 Z = 1.16 (P 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ntal Total 112 72 122 16 70 392 (P = 025) 69 69 = 0.45)	6, df = 1 (F Contr Events 3 2 2 1 3 3 11 05); I ² = 0 1 1	ol <u>Total</u> 112 77 122 16 69 396 % 61 61	Weight 23.0% 14.8% 15.3% 11.5% 23.2% 87.8% 12.2%	Risk Ratio M-H, Fixed, 95% CI 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81] 0.57 [0.22, 1.47] 0.30 [0.01, 7.12] 0.30 [0.01, 7.12]	Risk Ratio
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = (Test for overall effect: 3 miscarriage Kaandorp et al.2010 Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: 3 Total (95% CI) Total events	rences: Chi ^a e Experime Events 1 1 2 0 2 0.68, df = 4 Z = 1.16 (P 0 0 0 0 0 0 0 0 0 0 0 0 0	ntal Total 112 72 122 122 122 16 392 (P = 0.25) 69 69 69 69 69 461	6, df = 1 (F Contr Events 3 2 2 1 3 11 05); I ² = 0 ¹ 1 1 1	ol Total 112 77 122 16 69 396 % 61 61 61	Weight 23.0% 14.8% 15.3% 11.5% 23.2% 87.8% 12.2%	Risk Ratio M-H, Fixed, 95% CI 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81] 0.57 [0.22, 1.47] 0.30 [0.01, 7.12] 0.30 [0.01, 7.12]	Risk Ratio M-H, Fixed, 95% CI
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = (miscarriage Kaandorp et al.2010 Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: : Total (95% CI) Total events Heterogeneity: Chi ² = (rences: Chi ² e Experime Events 1 1 2 0 2 0.68, df = 4 Z = 1.16 (P 0 0 0 0 0 0 0 0 0 0 0 0 0	ntal Total 112 72 122 16 70 392 (P = 0.25) 69 69 69 69 69 461 (P = 0.45)	S, df = 1 (F Contr Events 3 2 2 1 3 11 25); I ² = 0' 1 1 1 207); I ² = 0'	ol Total 112 77 122 16 69 396 % 61 61 61	Weight 23.0% 14.8% 15.3% 11.5% 23.2% 87.8% 12.2%	Risk Ratio M-H, Fixed, 95% CI 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81] 0.57 [0.22, 1.47] 0.30 [0.01, 7.12] 0.30 [0.01, 7.12]	Risk Ratio M-H, Fixed, 95% Cl
Test for subgroup diffe HELLP syndrom Study or Subgroup history of PE Gris JC et al.2011 Groom et al.2017 Haddad et al.2016 Hoorn et al.2016 Hoorn et al.2016 Vries et al. 2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = (Test for overall effect: 3 miscarriage Kaandorp et al.2010 Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: 3 Total (95% CI) Total events	rences: Chi ² e Experime Events 1 1 2 0 2 6 0.68, df = 4 Z = 1.16 (P 0 0 0 0 0 0 0 0 0 0 0 0 0	ntal Total 112 72 122 16 70 392 (P = 0.25) 69 69 69 69 69 461 (P = 0.45) 461	Contri Events 3 2 2 1 3 3 11 25); I ² = 0 ⁻¹ 1 1 1 207); I ² = 0 ⁻¹	ol Total 112 77 122 16 69 396 396 % 61 61 457 %	Weight 23.0% 14.8% 15.3% 11.5% 23.2% 87.8% 12.2% 12.2% 100.0%	Risk Ratio M-H, Fixed, 95% Cl 0.33 [0.04, 3.16] 0.53 [0.05, 5.77] 1.00 [0.14, 6.99] 0.33 [0.01, 7.62] 0.66 [0.11, 3.81] 0.57 [0.22, 1.47] 0.30 [0.01, 7.12] 0.30 [0.01, 7.12] 0.30 [0.01, 7.12]	Risk Ratio M-H, Fixed, 95% CI

syndrome.




TABLE 2 Results of Egger's and Begg's tests.

Test	Begg's	Egger's
	P-value	
PE	0.02	0.007
live birth rate	0.13	0.30
placental abruption	0.18	0.06
SGA	0.45	0.67
sPE	0.73	0.51
gestational hypertension	1.00	0.98
FGR	0.46	0.58
fetal and neonatal death	0.27	0.13
HELLP syndrome	0.45	0.14
intrapartum or postpartum hemorrhage	1.00	0.70

women's history of PE or miscarriage, which is roughly the same as our study grouping criteria. The results of this study showed that the combination of drugs could not effectively reduce the incidence of PE and SGA in women with a history of miscarriage. However, after we increased the sample size, we came to a conclusion inconsistent with Roberge et al. (8). We found that in high-risk women, combination therapy not only reduced PE, but also reduced fetal and neonatal death.

Aspirin inhibits the production of prostaglandin and thromboxane A2 by irreversible acetylation of serine residues in the active center of cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2), and finally inhibits platelet aggregation (33), thereby reducing thrombosis. Aspirin can also inhibit the production of thromboxane and prostacyclin in trophoblast, thus effectively preventing the contraction of placental blood vessels and avoiding insufficient placental blood flow. Additionally, aspirin plays a therapeutic role in preeclampsia through anti platelet aggregation, prevention of oxidative stress, improvement of cell apoptosis, etc (34, 35).

LMWH strengthens its inactivation of coagulation factors IIa, IXa and Xa by combining with antithrombin, thus reducing the generation of corresponding coagulation factors. It not only has the effects of anticoagulant, preventing placental thrombosis and placental infarction (36), but also has the effects of anti-inflammatory, anti-tumor and promoting angiogenesis (10, 37). LMWH can promote the conversion of plasminogen to plasmin, reduce blood viscosity, change blood rheology, inhibit vasoconstriction, improve organ blood perfusion, protect vascular endothelium, strengthen placental exchange function, increase fetal urine volume and amniotic fluid volume, promote fetal growth and development, and improve perinatal prognosis (10). With further research, it was found that LMWH not only acts as an anticoagulant, but also has an obvious effect on the development and invasion of trophoblast (38). These results make LMWH as a potential drug for the prevention of PE and SGA.

Studies have shown that LDA combined with LMWH may offset the adverse reactions caused by some drugs and increase the effect of the two drugs (39). For pregnant women with underlying diseases, LDA should not be given only. For the impact of factors such as hypercoagulability and thrombophilia on placenta and fetus, anticoagulant drugs such as LMWH may also be needed (40). Our results also show that LMWH combined with LDA can significantly improve the pregnancy outcome of high-risk women without increasing the risk of bleeding.

The strengths of our study include the inclusion of more RCT studies and more patients comparing the effects of combination and single drug than other meta-analysis. Although there may be heterogeneity in our results, it also proves to some extent that our results are applicable to women with high risk factors for PE and its complications. At the same time, we also evaluated the bleeding risk of combined drugs, which is also a key safety index to be considered in the process of clinical use.

This study has some limitations. First, the quality grades of the included studies were inconsistent. Among them, five studies (20–22, 26, 29) did not adopt blind design, and the random allocation method of two studies (30, 31) was unclear. Second, because many women chose to withdraw from the trial study, there was uncertainty about the treatment compliance of the subjects. Third, four of all included RCTs in recurrent miscarriage did not report whether LMWH combined with LDA could reduce the incidence of PE. In addition, only three of the 14 included studies reported on intrapartum or postpartum hemorrhage, leading to publication bias in the results. Fourth, the study did not evaluate the impact of long-term maternal and infant outcomes. More large sample, multicenter and longterm follow-up studies are needed to confirm the long-term impact of combined drugs on maternal and infant outcomes. Finally, the Begg's and Egger's test results of PE showed potential publication bias, indicating that the statistical analysis results may be unstable, and it is recommended to carry out studies with higher quality and more rigorous experimental design.

Therefore, the efficacy of aspirin combined with LMWH is better than that of single drug, and can improve maternal and infant outcomes to a certain extent. It is worthy of clinical promotion, but it needs to be further verified by strictly designed, large sample and multi center randomized controlled trials.

Conclusion

The results of this meta-analysis showed that LMWH combined with LDA can effectively improve the pregnancy outcome of women with high risk factors and reduce the incidence of PE, SGA, gestational hypertension, fetal and neonatal death. At the same time, there are three studies that report women's bleeding. The results show that the combination of drugs does not increase the risk of bleeding, but such results lack the support of large sample size studies. The clinical safety analysis of LMWH combined with LDA in patients with PE should be more carried out.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

LZ and YaW planned and designed the study. LZ, BX, YY, and YuW screened studies and performed the systematic review and extracted data from included studies. YY, BX, and LZ analyzed the data and performed the quality assessment of studies. LZ drafted the manuscript. All authors contributed to the discussion section of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Chinese Peking Union Medical College, Basic Scientific Research Project of Central University (No. 2019XK320078, BJ-2019-092) and Sailing Project of Beijing Hospital Clinical Research in 2022 (BJ-2022-155).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

 Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. (2012) 36:56–9. doi: 10.1053/j.semperi.2011. 09.011

2. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The "great obstetrical syndromes" are associated with disorders of deep placentation. *Am J Obstet Gynecol.* (2011) 204:193–201. doi: 10.1016/j.ajog.2010. 08.009

3. Leaf RK, Connors JM. The role of anticoagulants in the prevention of pregnancy complications. *Clin Appl Thromb Hemost.* (2017) 23:116–23. doi: 10.1177/1076029615615972

4. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. *Placenta*. (2006) 27:939– 58. doi: 10.1016/j.placenta.2005.12.006 5. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. *Science*. (2005) 308:1592–4. doi: 10.1126/science.1111726

6. Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. *Lancet.* (2016) 387:999–1011. doi: 10.1016/S0140-6736(15) 00070-7

7. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review. *Placenta*. (2003) 24(Suppl A):S21-7. doi: 10.1053/plac.2002.0930

8. Roberge S, Demers S, Nicolaides KH, Bureau M, Côté S, Bujold E. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a metaanalysis. *Ultrasound Obstet Gynecol.* (2016) 47:548–53. doi: 10.1002/uog.15789

9. Cui Y, Zhu B, Zheng F. Low-dose aspirin at \leq 16 weeks of gestation for preventing preeclampsia and its maternal and neonatal adverse outcomes:

a systematic review and meta-analysis. *Exp Ther Med.* (2018) 15:4361–9. doi: 10.3892/etm.2018.5972

10. McLaughlin K, Baczyk D, Potts A, Hladunewich M, Parker JD, Kingdom JC. Low molecular weight heparin improves endothelial function in pregnant women at high risk of preeclampsia. *Hypertension*. (2017) 69:180–8. doi: 10.1161/HYPERTENSIONAHA.116.08298

11. Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. *Blood.* (2014) 123:822–8. doi: 10.1182/blood-2013-01-478958

12. Greer IA. Anticoagulants in pregnancy. J Thromb Thrombolysis. (2006) 21:57-65. doi: 10.1007/s11239-006-5578-5

13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097

14. Gestational hypertension and preeclampsia: ACOG practice bulletin summary, Number 222. *Obstet Gynecol.* (2020) 135:1492–5. doi: 10.1097/AOG.00000000003892

15. Lees CC, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F, et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestationalage fetus and fetal growth restriction. *Ultrasound Obstet Gynecol.* (2020) 56:298–312. doi: 10.1002/uog.22134

16. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ.* (2019) 366:14898. doi: 10.1136/bmj.14898

17. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons (2021). Available online at: https://training.cochrane.org/handbook/archive/v6.2

18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629

19. Karadag C, Akar B, Gönenç G, Aslancan R, Yilmaz N, Çalişkan E. Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation. J Matern Fetal Neonatal Med. (2020) 33:1934–9. doi: 10.1080/14767058.2019.1671348

20. Groom KM, McCowan LM, Stone PR, Chamley LC, McLintock C. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history - an open-label randomized trial (the EPPI trial): study protocol. *BMC Pregnancy Childbirth.* (2016) 16:367. doi: 10.1186/s12884-016-1162-y

21. van van Hoorn ME, Hague WM, van Pampus MG, Bezemer D, de Vries JI. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. *Eur J Obstet Gynecol Reprod Biol.* (2016) 197:168–73. doi: 10.1016/j.ejogrb.2015.12.011

22. Haddad B, Winer N, Chitrit Y, Houfflin-Debarge V, Chauleur C, Bages K, et al. Enoxaparin and aspirin compared with aspirin alone to prevent placentamediated pregnancy complications: a randomized controlled trial. *Obstet Gynecol.* (2016) 128:1053–63. doi: 10.1097/AOG.000000000001673

23. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepLDA trial. *J Rheumatol.* (2009) 36:279–87. doi: 10.3899/jrheum.080763

24. Elmahashi MO, Elbareg AM, Essadi FM, Ashur BM, Adam I. Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. *BMC Res Notes*. (2014) 7:23. doi: 10.1186/1756-0500-7-23

25. Gris JC, Chauleur C, Molinari N, Mares P, Fabbro-Peray P, Quere I. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. *Thromb Haemost.* (2011) 106:1053-61. doi: 10.1160/TH11-05-0340

26. de Vries JI, Van Pampus MG, Hague WM, Bezemer PD, Joosten JH, Fruit Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. *J Thromb Haemost.* (2012) 10:64–72. doi: 10.1111/j.1538-7836.2011.04553.x

27. Visser J, Ulander VM, Helmerhorst FM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. *Thromb Haemost.* (2011) 105:295–301. doi: 10.1160/TH10-05-0334

28. Kaandorp SP, Goddijn M, Van Der Post JA, Hutten BA, Verhoeve HR, Hamulyák K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. *N Engl J Med.* (2010) 362:1586–96. doi: 10.1056/NEJMoa1000641

29. Gris JC, Chauleur C, Faillie JL, Baer G, Marès P, Fabbro-Peray P, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. *The pilot randomised controlled NOH-AP trial*. *Thromb Haemost.* (2010) 104:771–9. doi: 10.1160/TH10-03-0167

30. Sergio F, Maria Clara DA, Gabriella F, Giorgia S, Sara DC, Giancarlo P, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus lowdose aspirin versus low-dose aspirin alone. *Hypertens Pregnancy*. (2006) 25:115– 27. doi: 10.1080/10641950600745517

31. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. *Med Sci Monit.* (2006) 12:CR132–6.

32. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. *Obstet Gynecol.* (2002) 100:408-13. doi: 10.1097/00006250-200212000-00032

33. Hossain N, Paidas MJ. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. *Semin Perinatol.* (2007) 31:208–12. doi: 10.1053/j.semperi.2007.05.002

34. Orendi K, Kivity V, Sammar M, Grimpel Y, Gonen R, Meiri H, et al. Placental and trophoblastic in vitro models to study preventive and therapeutic agents for preeclampsia. *Placenta*. (2011) 32:S49–54. doi: 10.1016/j.placenta.2010.11.023

35. Schröder H. Nitric oxide and aspirin: a new mediator for an old drug. Am J Ther. (2009) 16:17–23. doi: 10.1097/MJT.0b013e318164bd60

36. ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. *Obstet Gynecol.* (2018) 132:e44–52. doi: 10.1097/AOG.00000000002708

37. Mastrolia SA, Mazor M, Holcberg G. The physiologic anticoagulant and antiinflammatory role of heparins and their utility in the prevention of pregnancy complications. *Thromb Haemost.* (2015) 113:1236–46. doi: 10.1160/TH14-10-0848

38. Bolnick AD, Bolnick JM, Kohan-Ghadr HR, Kilburn BA, Pasalodos OJ, Singhal PK, et al. Enhancement of trophoblast differentiation and survival by low molecular weight heparin requires heparin-binding EGF-like growth factor. *Hum Reprod.* (2017) 32:1218–29. doi: 10.1093/humrep/dex069

39. Han CS, Mulla MJ, Brosens JJ, Chamley LW, Paidas MJ, Lockwood CJ, et al. Aspirin and heparin effect on bLDAl and antiphospholipid antibody modulation of trophoblast function. *Obstet Gynecol.* (2011) 118:1021-8. doi: 10.1097/AOG.0b013e31823234ad

40. Group of pregnancy induced hypertension, branch of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for the diagnosis and treatment of pregnancy induced hypertension. *Chin J Obst Gynecol.* (2020) 55:227–s38. doi: 10.3760/cma.j.cn112141-2020011 4-00039